The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Pituitary somatostatin receptor signaling
Open accessAbstract
Somatostatin (SRIF) is a major regulator of pituitary function, mostly inhibiting hormone secretion and to a lesser extent pituitary cell growth. Five SRIF receptor subtypes (SSTR1–5) are ubiquitously expressed G-protein coupled receptors. In the pituitary, SSTR1, SSTR2, SSTR3 and SSTR5 are expressed, with SSTR2 and SSTR5 predominating. As new SRIF-analogs have recently been introduced for treatment of pituitary disease, we evaluate the current knowledge of cell-specific pituitary SRIF receptor signaling and highlight areas of future research for comprehensive understanding of these mechanisms. Elucidating pituitary SRIF receptor signaling enables understanding of pituitary hormone secretion and cell growth, and also points to future therapeutic development for pituitary disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Giustina, A., & Veldhuis, J. D. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.6.0353 · Cited by 1,253
Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G., & Weckbecker, G. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460707 · Cited by 692
Pasireotide (SOM230): Development, mechanism of action and potential applications
Schmid, H. A. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.09.006 · Cited by 290 · cited 1×
“Pasireotide which binds all three receptor subtypes (SSTR5 > SSTR2 > SSTR1) was more effective in long term reduction of serum GH levels than octreotide in animal models; however, its advantage over octreotide which activates SSTR2 > SSTR5 but not SSTR1 in GH-secreting adenomas is yet unproven [103] and currently in c…”
BackgroundLow, M. J., Otero-Corchon, V., Parlow, A. F., Ramirez, J. L., Kumar, U., Patel, Y. C., & Rubinstein, M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11941 · Cited by 163
Farhy, L. S., & Veldhuis, J. D. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00473.2003 · Cited by 55
Cited by
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Pathogenesis of pituitary tumors
Melmed, S. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.40 · Cited by 466
Self-citationGünther, T., Tulipano, G., Dournaud, P., Bousquet, C., Csaba, Z., Kreienkamp, H.-J., Lupp, A., Korbonits, M., Castaño, J. P., Wester, H.-J., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015388 · Cited by 253
Self-citationThe intricate role of growth hormone in metabolism
Vijayakumar, A., Yakar, S., & LeRoith, D. (2011) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00032 · Cited by 179
SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells
Kailey, B., van de Bunt, M., Cheley, S., Johnson, P. R., MacDonald, P. E., Gloyn, A. L., Rorsman, P., & Braun, M. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00207.2012 · Cited by 164
Metadata
- Authors
- Ben-Shlomo, A., & Melmed, S.
- Venue
- Trends in Endocrinology & Metabolism
- Publisher
- Elsevier BV
- Published
- 2010-03
- Volume
- 21
- Issue
- 3
- Pages
- 123-133
- ISSN
- 1043-2760 (ISSN-L)
- OpenAlex
- W1986480183
- Cited by
- 213
- References
- 5
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pituitary somatostatin receptor signaling. https://app.cochat.ai/papers/10.1016/j.tem.2009.12.003
- The paper
- Ben-Shlomo, A., & Melmed, S. (2010). Pituitary somatostatin receptor signaling. Trends in Endocrinology & Metabolism. https://doi.org/10.1016/j.tem.2009.12.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.